Nemvaleukin alfa (Nemvaleukin) has been granted fast-track designation by the FDA for the treatment of patients with mucosal melanoma who have received prior treatment with an anti–PD-L1 therapy, according to a press release from Alkermes.1
Publications
FDA Sets PDUFA Date for Pembrolizumab
Merck announced that its phase 3 KEYNOTE-716 (NCT03553836) trial investigating pembrolizumab (Keytruda) has met its primary endpoint…
Clinical characteristics and prognosis of acral lentiginous melanoma: A single-center series of 211 cases in China
Researchers conducted this retrospective observational study to summarize and analyze the clinical features, treatment strategy, treatment effect, and prognostic factors of acral lentiginous melanoma (ALM) in a Chinese population.
Diagnosis of melanoma by imaging mass spectrometry: Development and validation of a melanoma prediction model
This study sought to report the development and validation of a melanoma prediction model from spatially resolved multivariate protein expression profiles generated by Imaging Mass Spectrometry (IMS).